| Hazard Information | Back Directory | [Uses]
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis[1]. | [in vivo]
Aldometanib (oral; 0-10 mpk) reduces blood glucose in lean mice[1].
?
Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice[1].
?
Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis[1].
?
Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice[1].
?
Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan in C. elegans via the lysosomal pathway[1]. | Animal Model: | Lean mice[1] | | Dosage: | 0-10 mpk | | Administration: | Oral | | Result: | Decreased fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake. |
| Animal Model: | Obese hyperglycaemic mice[1] | | Dosage: | 2-10 mpk | | Administration: | Oral, twice daily, for a week | | Result: | Decreased blood glucose, lowered blood glucose in a muscular AMPK-dependent manner reduced hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, decreased fat mass. |
| Animal Model: | NASH mice[1] | | Dosage: | 2 mpk | | Administration: | Oral, twice-daily, for a month | | Result: | Decreased histological scores used to describe the features of NASH, reduced apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice. |
| Animal Model: | C. elegans[1] | | Dosage: | 0-50 μM | | Administration: | Oral, 0-50 days | | Result: | Promoted oxidative stress resistance and mitochondrial functions in C. elegans. |
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 100 μg/mL | | Administration: | Oral | | Result: | Extended lifespan, elevated NAD＋ levels and mitochondrial oxidative respiration, rejuvenated muscle function in aged mice. |
| [References]
[1] Chen-Song Zhang, et al. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat Metab. 2022 Oct 10. DOI:10.1038/s42255-022-00640-7 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|